⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Official Title: Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Study ID: NCT01611259

Study Description

Brief Summary: This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting with measurable disease.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

AKH Linz, Linz, Oberösterreich, Austria

Klin.Abt.f. Hämatologie; Med.Univ.Graz, Graz, , Austria

Univ.-Klinik f. Innere Medizin V, Innsbruck, , Austria

PMU Salzburg, Salzburg, , Austria

Universitätsklinik f. Innere Medizin I, Vienna, , Austria

Contact Details

Name: Markus Raderer, MD

Affiliation: Allgemeines Krankenhaus der Stadt Wien - Medizinischer Universitätscampus

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: